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Vascular wall proteoglycan synthesis and structure 
as a target for the prevention of atherosclerosis
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Abstract: Atherosclerosis is the underlying pathology of most cardiovascular disease and it 
represents the major cause of premature death in modern societies. Current therapies target risk 
factors being hypertension, hypercholesterolemia, hypertriglyceridemia and hyperglycemia when 
diabetes is present however the maximum efﬁcacy of these strategies is often 30% or less. Areas of 
vascular biology that may lead to the development of a complementary vascular wall directed therapy 
are: inﬂammation, oxidation, endothelial dysfunction, diabetes-speciﬁc factors —hyperglycemia and 
advanced glycation endproducts and lipid retention by vascular matrix speciﬁcally proteoglycans. The 
major structural features of proteoglycans that determine low-density lipoprotein (LDL) binding are 
the length and sulfation pattern on the glycosaminoglycan (GAG) chains. Emerging data discussed 
in this review indicates that these structural properties are subject to considerable regulation 
by vasoactive substances possibly using novel signaling pathways. For example, GAG elonga-
tion stimulated by platelet-derived growth factor is not blocked by the receptor tyrosine kinase 
antagonist, genistein suggesting that there may be a previously unknown signaling pathway 
involved in this response. Thus, modifying proteoglycan synthesis and structure may represent 
a prime target to prevent LDL binding and entrapment in the vessel wall and thus prevent the 
development and progression of atherosclerosis.
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Introduction
The World Health Organization estimates that cardiovascular diseases are responsible 
for 30 percent of all deaths worldwide each year, with atherosclerotic vascular disease 
the principal cardiovascular disorder responsible for the global rise in mortality (Bonow 
et al 2002). Combined with the explosion in the rates of obesity and type 2 diabetes, 
an unprecedented increase in the incidence of cardiovascular disease is predicted for 
the future. Atherosclerotic vascular disease is potentially preventable by lifestyle 
changes, therapeutics or a combination of both strategies.
Atherosclerosis is the result of a complex interaction between lipoproteins, 
extracellular matrix and cells of the vessel wall leading to the formation of a lesion 
known as an atherosclerotic plaque. A signiﬁcant and potentially fatal outcome is 
acute plaque rupture leading to the formation of a thrombus—which may occlude 
the blood vessel at the rupture point or downstream causing ischemia and necrosis 
of affected tissues (Glass and Witztum 2001; Libby 2003). Current therapies target 
“risk factors” that contribute to increased incidence of cardiovascular disease, such as 
hypertension, hypercholesterolemia, hypertriglyceridemia, and hyperglycemia when 
diabetes is present. The maximum efficacy of these strategies as determined from 
multiple clinical trials is limited to around 30% (Pignone et al 2000). Notably, 
although atherosclerosis occurs within the vessel wall there is no pharmaceutical 
treatment that directly targets the blood vessel wall and is capable of preventing 
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the atherosclerotic process. Appropriate new target 
molecules are urgently needed to provide complementary 
anti-atherosclerotic therapies that may add to the success 
of risk factor directed strategies. This issue is well 
recognized by the pharmaceutical industry as expressed 
by Novartis Institutes for BioMedical Research: “Despite 
significant improvement in the prognosis of atheroscle-
rosis patients treated with statins, the disease process 
continues to progress in a significant proportion of pa-
tients. Thus, alternative (or adjunctive) novel therapies 
that inhibit other triggers for this pathological state are 
needed…” (www.novartisinstitutes.com/DiseaseAreas/
Cardiovascular/)
Thus, there is widespread agreement on the successful 
role of statins and other cardiovascular risk factor directed 
strategies but importantly there is also acknowledgement of 
a large amount of resistant or residual disease (atheroscle-
rosis). With two decades of vascular biology research and 
considerably increased knowledge of the molecular and cel-
lular mechanisms of atherosclerosis an opportunity for the 
identiﬁcation of new therapeutic targets and the development 
of targeted drugs is available.
The major areas of research that may potentially   
provide a vascular directed agent for the prevention of   
atherosclerosis are: inflammation (Ross 1999; Libby 
2006), oxidation (Steinberg et al 1989; Witztum 1994; 
Stocker and Keaney 2004), endothelial dysfunction 
(Davignon and Ganz 2004), diabetes specific factors—
hyperglycemia and advanced glycation end products 
(AGEs) (Brownlee 2001; Forbes et al 2004), and lipid 
retention by vascular matrix specifically proteoglycans 
(Skalen et al 2002).
Special attention is given to the area of lipid reten-
tion as favored by our laboratory for the following 
reasons: firstly lipid retention is an essential and very 
early step in the atherosclerotic cascade indeed with-
out this event atherosclerosis cannot be induced in 
animal models of the disease (reviewed in Olofsson and 
Boren 2005); secondly, proteoglycans are the major 
lipid-binding component present in the arterial wall 
able to interact with lipids in the early stages of ath-
erosclerotic plaque development (Camejo 1982; Skalen   
et al 2002); thirdly, signaling pathways of proteoglycan 
and glycosaminoglycan (GAG) structural changes appear 
to be highly novel and provide tissue and pathological 
specificity and fourthly, the turnover of proteoglycans is 
sufficiently high to provide an opportunity for therapeutic 
modification of the extracellular matrix. 
Low density lipoprotein binding 
to proteoglycans—the “response  
to retention” hypothesis
The “response to retention hypothesis proposes that sub-
endothelial retention of lipoproteins by matrix proteoglycans, 
most prominently chondroitin sulfate (CS)/dermatan sulfate 
(DS) proteoglycans is a critical initiating step in atherogenesis 
(Williams and Tabas 1995). The binding of lipoproteins to these 
molecules leads to their entrapment and eventual phagocytosis by 
macrophages and other cells. Therefore understanding the precise 
mechanisms by which lipid is trapped and retained within blood 
vessels is critical to understanding atherogenesis and may provide 
targets for new therapies aimed at reducing plaque formation by 
directly targeting the vascular wall.
A study reported in Nature by the Boren Laboratory 
in Gothenburg in 2002 supported not only the “response 
to retention hypothesis” but also speciﬁcally the role of 
proteoglycans in lipoprotein binding (Skalen et al 2002). 
Transgenic mice expressing human wild-type apoB100 
containing low-density lipoprotein (LDL) with normal 
proteoglycan binding or genetically altered LDL such that 
LDL-proteoglycan binding was defective were generated. After 
20 weeks of feeding on a Western diet, mice with mutations of 
the apoB100 gene developed signiﬁcantly less atherosclerosis 
due to the decreased ability of apoB100-modiﬁed LDL to bind 
with artery wall proteoglycans. This study presents direct 
evidence that the binding of LDL to proteoglycans in the 
blood vessel wall is a key step in atherogenesis. The authors 
concluded “thus, atherosclerosis is initiated by sub-endothelial 
retention of atherogenic lipoproteins”. In an associated com-
mentary it was stated “… therapies that act directly on the 
arterial wall are needed” (Staels 2002). 
LDL normally passes through the blood vessel wall by 
a process of endothelial transcytosis and efﬂux through the 
vessel wall (see Nigro et al 2006). Retention of LDL within 
the vessel wall and efﬂux to the lymph are rate-limiting 
steps (Proctor 2002). GAG chains on proteoglycans are 
highly negatively charged with over 90% of the disaccharide 
moieties containing an ionized sulfate group and all contain 
an ionized carboxylic acid group. The only manner in which 
the contribution of apo B100 on the LDL can be altered is by 
lowering the concentration in the plasma. It is not a viable 
therapeutic option to alter the protein sequence by the genetic 
manipulation employed by Boren and colleagues in their 
mouse study (Skalen et al 2002). Therefore, an alternative 
approach is to modify the synthesis and structure of the 
proteoglycans in the vessel wall. Vascular Health and Risk Management 2007:3(1) 119
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Camejo and colleagues (1993) described an in vitro assay, 
somewhat equivalent to a receptor-binding assay, in which 
the binding of radiolabelled proteoglycans to LDL can be 
studied rapidly. Many vasoactive agonists and hormones 
have been shown to increase the size of the GAG chains 
on proteoglycans and in many cases (using the Camejo 
methodology) it has been demonstrated that this leads to 
greater binding to LDL. There have been only a few studies 
on the possibility of inhibiting this GAG elongation. 
Our laboratory is addressing the question of inhibiting 
atherogenic changes in GAG synthesis and structure as a 
strategy to prevent atherosclerosis. In the late 1990s we 
embarked on a major program to study the hormonal and 
metabolic factors and their signaling pathways controlling 
GAG synthesis and structure on vascular smooth muscle 
proteoglycans. The most notable ﬁnding in the ﬁeld at that 
time was the work of Schonherr et al (1997) in the Wight 
Laboratory in Seattle which showed that platelet derived 
growth factor (PDGF)-mediated elongation of GAG chains 
on proteoglycans synthesized by primate vascular smooth 
muscle cells (VSMCs) was not blocked by genistein. On 
the basis that genistein was a broad-spectrum tyrosine 
kinase inhibitor it was concluded that genistein-sensitive (ie, 
most if not all) tyrosine kinases were not involved in GAG 
elongation. This is a very important statement because it 
implies signaling via the PDGF receptor that is independent 
of the receptor tyrosine autophosphorylation which is the 
“classic” signaling pathway for PDGF receptor signaling, 
for example in cell proliferation (Little et al 2003). Thus 
regulation of proteoglycan (PG) synthesis and structure, 
speciﬁcally GAG structure may be through novel signaling 
pathways and investigations of such pathways may lead to 
important information on the regulation of PG synthesis 
but also new information on signaling in vascular smooth 
muscle.
GAG elongation
The biochemical mechanisms by which the regulation 
of elongation of CS/DS chains of PGs occurs and spe-
ciﬁcally the factors that control ﬁnal GAG chain length 
are unknown. Possible mechanisms include the activity of 
the multitude of chain elongation enzymes, the activity of 
the transporters that provide the requisite substrates and 
the transition time of the growing GAG chain through the 
Golgi synthetic process. As the importance of GAG chain 
length in PG function continues to increase it will become 
very important to understand the processes controlling 
GAG elongation. Many factors have been found to elongate 
GAG chains and these include growth factors such as PDGF 
(Schonherr et al 1993) and transforming growth factor-β 
(TGFβ) (Little et al 2002), vasoactive hormones such as   
angiotensin II (Figueroa and Vijayagopal 2002), and meta-
bolic factors such as oxidized LDL (Chang et al 2000) and 
free fatty acids (Olsson et al 1999). As the activated ves-
sel wall contains multiple growth factors and vasoactive 
substances, we recently considered if the interaction of 
these agents might have an additive effect on GAG elon-
gation—both PDGF and TGFβ (at maximally effective 
doses) increase GAG length and these effects are clearly 
additive (Figure 1). Matrix can control the length of GAG 
chains (Figueroa et al 2004) but this is most likely secondary to 
a role in controlling proliferation since increased proliferation 
is associated with elongation of GAG chains of proteoglycans. 
One drug family—the HMGCoA reductase inhibitors (statin 
drugs) —also elongate GAG chains on vSMCs PGs (Meyers 
et al 2003). In most of these cases it has been demonstrated 
that the elongated GAG chains are associated with an in-
creased proteoglycan/LDL binding. The only exception is 
the PGs secreted by statin treated cells in which the GAG 
elongation effect is overwhelmed by an inhibitory effect on 
sulfation as discussed below.
The process of GAG elongation is controlled indepen-
dently from the presence of the PG core protein. Cells can be 
provided with exogenous “xyloside”—the ﬁrst sugar attached 
to the serine of the core protein in the tetrasaccharide linker 
regions preceding the GAG chain—and short GAGs will be 
synthesized on that xyloside. The resultant molecules are 
about 10–15 kDa and thus a quarter of the size of the GAG 
chains on normal PGs. The size of the xyloside GAGs is regu-
lated in parallel with the effects on GAG chains of PGs—for 
example TGFβ stimulates elongation of GAG chains on PGs 
and also elongation of xyloside GAGs in human VSMCs. 
Interestingly, although the afﬁnity of binding LDL is almost 
one order of magnitude lower for binding to xyloside GAGs 
compared with free chains, the enhanced LDL binding is 
also observed in xyloside GAGs from TGFβ-treated cells 
(Little et al 2002). 
The signaling pathways through which agents stimulate 
GAG elongation are poorly understood but potentially of 
immense importance as drug targets. It is most likely that 
the signaling pathways will provide the tissue and disease 
speciﬁcity required for the development of a therapeutic 
agent in this area. The most intriguing ﬁnding is that the 
action of PDGF to elongate GAG chains on VSMC PGs 
is not blocked by genistein (Schonherr et al 1997). In PG 
synthesis by primate VSMCs, genistein inhibits the expression Vascular Health and Risk Management 2007:3(1) 120
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of the core protein for versican so this appears to be via the 
classic signaling pathway (Figure 2). There are only a very 
small number of responses to PDGF which are not sensitive 
to genistein (Mundschau et al 1994; Pelletier and Boynton 
1994; Cartel et al 2001). The possibility that there is a com-
pletely novel PDGF signaling pathway controlling GAG 
elongation is intriguing. TGFβ also signals GAG elonga-
tion. The biochemically similar signaling pathway to the 
tyrosine kinase activity of the PDGF receptor would be the 
serine/threonine kinase activity of the TGFβ Type 1 receptor 
(ALK-5) which phosphorylates Smad proteins (Agrotis et al 
2005). An inhibitor of ALK-5 has recently become available 
(Inman et al 2002). This compound will be able to be used to 
assess if the GAG elongation mediated by TGFβ is through 
the classic serine/threonine kinase pathway associated with 
collagen synthesis and ﬁbrosis and thus whether the signaling 
pathway for PDGF is itself unique or indicative of a new set 
of growth factor signaling pathways associated with CS/DS 
GAG synthesis.
The process of GAG elongation is susceptible to pharma-
cological inhibition. Receptor mediated elongation such as 
for Ang II can be blocked by receptor antagonists (Figueroa 
and Vijayagopal 2002). Signaling pathway antagonists such 
as the MAP kinase inhibitor PD98059 (Shimizu-Hirota   
et al 2001) block the action of Ang II and epidermal 
growth factor receptor (EGFR) transactivation by Ang II 
is blocked by EGFR inhibitor AG1478 (Shimizu-Hirota 
et al 2001). A multitude of cardiovascular agents block 
GAG elongation and represent pleiotropic actions of 
these drugs. The peroxisome proliferator-activated re-
ceptor-α (PPARα) ligands, the lipid-lowering ﬁbrates 
gemﬁbrozil and fenoﬁbrate (Wiklund et al 1996; Nigro 
et al 2002, 2004), block GAG elongation and reduce 
lipid LDL binding. The PPARγ ligands, the insulin-
sensitizing thiazolidinediones, rosiglitazone, and piogli-
tazone (Tannock et al 2004; Rodriguez-Lee et al 2006) 
as well as the experimental agent darglitazone (Olsson   
et al 1999), block GAG elongation and reduce LDL binding 
to PGs. Calcium channel blockers inhibit GAG elongation 
(Vijayagopal and Subramaniam 2001) but the mechanism is 
not dependent upon inhibition of voltage-sensitive calcium 
channels (Survase et al 2005). 
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Figure 1 Stimulation of vascular smooth muscle cells with both TGF-β1 and PDGF has an additive effect to increase [35S]-sulfate incorporation into proteoglycans.
Human VSMC treated with DMEM (–), PDGF (P, 50 ng/ml), TGF-β1 (T; 1 ng/mL) or PDGF plus TGF-β1 (P + T; 50 ng/mL and 1 ng/mL respectively) for 24 h were metaboli-
cally labelled with 35S-SO4. (A) 
35SO4-labeled proteoglycans secreted into the medium were analyzed by CPC precipitation. (B) SDS-PAGE analysis of secreted PGs. 20 000 
cpm were loaded per lane. Gels were visualized by phospho-imaging.  
Abbreviations: PDGF: platelet-derived growth factor; TGF: transforming growth factor;  VSMC: vascular smooth muscle cell.Vascular Health and Risk Management 2007:3(1) 121
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Many of these cardiovascular drugs reduce atherosclero-
sis in animal models of the disease. For example rosiglitazone 
inhibits the development of atherosclerosis in ApoE KO mice 
rendered diabetic with streptozotocin (Calkin et al 2005). 
Troglitazone also blocks the development of atherosclerosis 
in mice (Collins et al 2001). A multitude of anti-atherogenic 
processes are considered as the mechanisms resulting in a 
reduction in atherosclerosis, but it is also likely that an inhibi-
tion of GAG elongation leading to reduced LDL retention in 
the vessel wall may also be a positive contributing factor.
It will be very interesting to determine if a highly 
speciﬁc and potent inhibitor of GAG elongation can be 
developed. Such a compound could be used in animal 
models to test the potential for a therapeutic agent based on 
inhibition of GAG to be developed for human therapeutic 
use. Currently to elucidate the potential side effects of PG 
and GAG modiﬁcations it is necessary to examine the con-
sequences of mutant PG genes in human patients and gene 
manipulation in mouse models. The extensive involvement 
of PGs in extracellular matrix and tissue stability as well as 
their roles in growth factor signaling indicate the potential 
areas of impact PG and GAG alterations may inﬂuence. 
Regulation of PG and GAG chain biosynthesis and me-
tabolism is implicated in numerous human disease states 
(Ballinger et al 2004). To date at least 11 genes encoding 
PGs have been ablated in mice including biglycan, decorin, 
versican and perlecan (Aszodi et al 2006) with some gene 
knockouts resulting in embryonic lethality, eg, versican 
and perlecan, while others show mild to severe phenotypes 
(Aszodi et al 2006). Perlecan-null mice (Hspg2–/–) are either 
embryonic lethal or die at birth and have a severe cartilage 
defect which presents as a disorganized growth plate with   
impaired chondrocyte proliferation and differentiation. 
These abnormalities arise from perlecan no longer being 
available to bind and regulate matrix metalloproteinases 
and thereby block the degradation of the collagen ﬁbrils 
in cartilage (Costell et al 1999) as well as resulting in 
impaired FGF-2 signaling (Arikawa-Hirasawa et al 1999). 
Mice expressing perlecan that lack attachment sites for three 
heparan sulfate chains (Hspg2∆3/∆3) survive but have defec-
tive eye lenses (Rossi et al 2003) demonstrating the capacity 
for altered PG molecules to result in altered phenotypes 
with variable severity. Undoubtedly it will be necessary to 
employ mouse knock-in models with speciﬁc PG and/or 
GAG mutations to provide a clearer identiﬁcation of the 
consequences of speciﬁc PG and GAG modiﬁcations.
GAG sulfation
A major structural feature of CS/DS GAG chains is the 
sulfation pattern. Disaccharide units can be sulfated on the 
Figure 2 PDGF-mediated signaling pathways for proteoglycan synthesis have classic and novel components. The PDGF stimulated signaling pathway for proteoglycan core 
protein expression is of the classic type as associated with proliferation and is sensitive to the PDGF receptor tyrosine kinase inhibitor, genistein. GAG elongation is not 
sensitive to genistein and the effect of genistein on the PDGF effect to increase the 6:4 sulfation ratio is unknown. The implication is that GAG elongation may be mediated 
by a completely novel PDGF signaling pathway which would provide an opportunity for the development of a speciﬁc therapeutic agent targeting GAG elongation but not 
other PDGF responses. 
Abbreviations: GAG: glycosaminoglycan; PDGF: platelet-derived growth factor.Vascular Health and Risk Management 2007:3(1) 122
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4 and 6 positions of the N-Acetylgalactosamine (GalNAc) 
moiety or the 2’ position on the uronic acid (GlcA) moiety 
(see Figure 3). As is the case for GAG elongation very 
little is currently known of the actual enzymes mediating 
CS/DS GAG sulfation in VSMC. The temporal aspects of 
sulfation are known, with 6 position sulfation occurring before   
the sulfation at the 4 position of the disaccharide. In VSMC the 
GAG product contains about 80%–90% monosulfation at the 4 
position and 5% at the 6 position with negligible amounts of 2’ 
position sulfation observed (Ballinger et al 2004). The temporal 
aspects can be demonstrated using sodium chlorate, which is 
a speciﬁc inhibitor of 4 position sulfation—in the presence of 
increasing concentrations of chlorate there is a decreasing amount 
of the sulfation at the 4 position (Ballinger et al 2004). 
Growth factors can regulate the sulfation pattern on 
GAGs. PDGF stimulates an increase in 6:4 position sulfation 
ratio of monosulfated disaccharides (Schonherr et al 1993). In 
contrast TGFβ does not alter the 6:4 position sulfation ratio 
in monkey arterial SMCs (Schonherr et al 1993), although as 
noted above both growth factors cause elongation of GAG 
chains on VSMC PGs. 
The most prominent sulfation positions on GAGs have 
different impacts on the biochemistry in relation to LDL 
binding. Sulfation at the 6 position is present on an exocyclic 
carbon and is thus more sterically accessible to an anionic 
binding site on the ApoB100 on LDL (Boren et al 1998). 
Sulfation at the 4 position produces an entity of apparently 
higher peak charge density compared with the 6-sulfated   
disaccharide as suggested by the increased migration on the 
charge-based FACE separation system (Ballinger et al 2004). 
There has been little work on the impact of GAG sulfation 
on LDL binding. Disaccharides derived from PGs from the 
atherosclerosis susceptible White Carneau pigeon have a 
higher 6:4 position sulfation ratio than the atherosclerosis-
resistant Show Pigeon (Edwards and Wagner 1988) and 
display higher binding afﬁnity for plasma LDL (Steele and 
Wagner 1987). This sulfation pattern of GAGs is typical of 
PGs at aortic atherosclerotic lesion prone-regions (Curwen 
and Smith 1977). 
Nothing is known of the signaling pathways that con-
trol sulfation of GAGs. As PDGF stimulates an increase 
in the 6:4 position sulfation ratio it will be very interesting   
to determine if this response is sensitive or resistant to genis-
tein —this will indicate whether or not the signaling pathway 
for two properties of GAG structure—elongation and sul-
fation —are both mediated via the novel genistein-resistant 
Figure 3 A chondroitin sulfate disaccharide unit and a dermatan sulfate disaccharide unit showing theoretical sulfation positions R = SO3
–.
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PDGF pathway or that only the elongation pathway is novel 
(Figure 2). It will be interesting to determine if the action 
of PDGF, and any other factors which may affect sulfation, 
leads to enhanced LDL binding speciﬁcally due to a change 
in sulfation pattern. If both 6 position sulfation and GAG 
elongation turn out to enhance LDL binding and thus be 
potentially pro-atherogenic then developing an agent that 
inhibits both of these responses will be critical. If it evolves 
that both these responses are regulated through the same 
pathway then the potential therapeutic agent will be effective 
in blocking both atherogenic responses. 
Few agents have been studied for their effects on sul-
fation pattern. The lipid-lowering ﬁbrate, fenoﬁbrate, does 
not affect the sulfation pattern of proteoglycans secreted by 
control or TGFβ-treated VSMCs (Nigro et al 2004) although 
this study did not examine the effect on PDGF, which in 
contrast to TGFβ actually increases the 6:4 position sulfation 
ratio. Several statin drugs inhibit radiosulfate incorporation 
into proteoglycans in primate vSMCs (Meyers et al 2003). 
Although the statin effect was observed in the presence of 
proliferating VSMCs and statins inhibit proliferation, the 
effect was observed when corrected for radiosulfate incor-
poration on a per cell basis (Meyers et al 2003). As noted 
above statins somewhat anomalously cause GAG chain elon-
gation. PGs from statin-treated cells show reduced binding 
to LDL (Meyers et al 2003). In this situation, hyposulfation 
of the GAG chains appears to greatly contribute to the net 
outcome of decreased proteoglycan/LDL binding observed, 
over-riding the effect of GAG chain elongation. The effect 
of statins to inhibit GAG sulfation is intriguing and warrants 
further investigation.
Conclusions
There is a great need and a large therapeutic window for the 
development of a vascular-directed agent that acts in concert 
with existing cardiovascular risk factor directed strategies 
to prevent atherosclerosis. Numerous potential mechanisms 
of action have emerged from the last several decades of   
research in vascular biology and pathology and these are being   
actively investigated in cell and animal systems. None has yet 
reached the clinic. Of the possible mechanisms one pathway 
is based on the role of vascular proteoglycans in the very early 
step of retaining lipid in the vessel wall. This retention occurs 
on the CS/DS GAG chains of proteoglycans and it has been 
demonstrated that changes in the GAG chains increase lipid 
binding in vitro. Modiﬁcation of GAG chain synthesis and 
biochemical structure provides a pathway that may be drug 
targeted. The investigation and development of agents which 
modify GAG chain synthesis needs to be actively pursued 
in order to ascertain the extent of the potential to reduce 
atherosclerosis and cardiovascular disease.
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